SEARCH

SEARCH BY CITATION

Reference

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153156.
  • 2
    Hashem B, El-Serag. Hepatocellular carcinoma. N Engl J Med 2011; 365: 11181127.
  • 3
    Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: current management. Curr Probl Surg 2010; 47: 1067.
  • 4
    Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. HEPATOLOGY 2000; 32: 12241229.
  • 5
    Hanish SI, Knechtle SJ. Liver transplantation for the treatment of hepatocellular carcinoma. Oncology (Williston Park) 2011; 25: 752757.
  • 6
    Kruskal JB, Kane RA. Intraoperative US of the liver: techniques and clinical applications. Radiographics 2006; 26: 10671084.
  • 7
    Postema M, Gilja OH. Contrast-enhanced and targeted ultrasound. World J Gastroenterol 2011; 17: 2841.
  • 8
    Sontum PC. Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging. Ultrasound Med Biol 2008; 34: 824833.
  • 9
    Watanabe R, Matsumura M, Chen CJ, Kaneda Y, Ishihara M, Fujimaki M. Gray-scale liver enhancement with Sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull 2003; 26: 12721277.
  • 10
    Mandai M, Koda M, Matono T, Nagahara T, Sugihara T, Ueki M, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol 2011; 84: 499507.
  • 11
    Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, et al. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol 2012; 47: 477485.
  • 12
    Sugimoto K, Shiraishi J, Moriyasu F, Saito K, Doi K. Improved detection of hepatic metastases with contrast-enhanced low mechanical-index pulse inversion ultrasonography during the liver-specific phase of sonazoid: observer performance study with JAFROC analysis. Acad Radiol 2009; 16: 798809.
  • 13
    Mitsunori Y, Tanaka S, Nakamura N, Ban D, Irie T, Noguchi N, et al. Contrast-enhanced intraoperative ultrasound for hepatocellular carcinoma: high sensitivity of diagnosis and therapeutic impact. J Hepatobiliary Pancreat Sci 2012; doi:10.1007/s00534-012-0507-9.
  • 14
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249257.
  • 15
    Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298307.
  • 16
    Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 13881393.
  • 17
    Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000; 60: 36833688.
  • 18
    Tanaka S, Arii S. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 2006; 11: 8289.
  • 19
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378390.
  • 20
    Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, Wands JR, et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. HEPATOLOGY 2002; 35: 861867.
  • 21
    Toyoda H, Fukuda Y, Hayakawa T, Kumada T, Nakano S. Changes in blood supply in small hepatocellular carcinoma: correlation of angiographic images and immunohistochemical findings. J Hepatol 1997; 27: 654660.
  • 22
    Ogawa S, Kumada T, Toyoda H, Ichikawa H, Kawachi T, Otobe K, et al. Evaluation of pathological features of hepatocellular carcinoma by contrast-enhanced ultrasonography: comparison with pathology on resected specimen. Eur J Radiol 2006; 59: 7481.
  • 23
    Sugimoto K, Moriyasu F, Kamiyama N, Metoki R, Yamada M, Imai Y, et al. Analysis of morphological vascular changes of hepatocellular carcinoma by microflow imaging using contrast-enhanced sonography. Hepatol Res 2008; 38: 790799.
  • 24
    Asayama Y, Yoshimitsu K, Nishihara Y, Irie H, Aishima S, Taketomi A, et al. Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. AJR Am J Roentgenol 2008; 190: 2834.
  • 25
    Tarhan NC, Hatipoğlu T, Ercan E, Bener M, Keleş G, Başaran C, et al. Correlation of dynamic multidetector CT findings with pathological grades of hepatocellular carcinoma. Diagn Interv Radiol 2011; 17: 328333.
  • 26
    Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 24632472.
  • 27
    Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 19952004.
  • 28
    Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 2010; 52: 6371.
  • 29
    Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, et al. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 2011; 253: 94100.
  • 30
    Yoshitake K, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, et al. Importin-α1 as a novel prognostic target for hepatocellular carcinoma. Ann Surg Oncol 2011; 18: 20932103.
  • 31
    Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95: 611619.
  • 32
    Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo; 2010.
  • 33
    Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 2006; 98: 491498.
  • 34
    Sugimoto K, Shiraishi J, Moriyasu F, Ichimura S, Metoki R, Doi K. Analysis of intrahepatic vascular morphological changes of chronic liver disease for assessment of liver fibrosis stages by micro-flow imaging with contrast-enhanced ultrasound: preliminary experience. Eur Radiol 2010; 20: 27492757.
  • 35
    Nanashima A, Tobinaga S, Abo T, Kunizaki M, Takeshita H, Hidaka S, et al. Usefulness of sonazoid-ultrasonography during hepatectomy in patients with liver tumors: a preliminary study. J Surg Oncol 2011; 103: 152157.
  • 36
    Arita J, Takahashi M, Hata S, Shindoh J, Beck Y, Sugawara Y, et al. Usefulness of contrast-enhanced intraoperative ultrasound using sonazoid in patients with hepatocellular carcinoma. Ann Surg 2011; 254: 992999.
  • 37
    Xouri G, Dimaki M, Bastiaens PI, Lygerou Z. Cdt1 interactions in the licensing process: a model for dynamic spatiotemporal control of licensing. Cell Cycle 2007; 6: 15491552.
  • 38
    Karamitros D, Kotantaki P, Lygerou Z, Veiga-Fernandes H, Pachnis V, Kioussis D, et al. Life without geminin. Cell Cycle 2010; 9: 31813185.
  • 39
    Noguchi K, Vassilev A, Ghosh S, Yates JL, DePamphilis ML. The BAH domain facilitates the ability of human Orc1 protein to activate replication origins in vivo. EMBO J 2006; 25: 53725382.
  • 40
    DePamphilis ML, Blow JJ, Ghosh S, Saha T, Noguchi K, Vassilev A. Regulating the licensing of DNA replication origins in metazoa. Curr Opin Cell Biol 2006; 18: 231239.
  • 41
    Blow JJ, Gillespie PJ. Replication licensing and cancer—a fatal entanglement? Nat Rev Cancer 2008; 8: 799806.
  • 42
    Wohlschlegel JA, Kutok JL, Weng AP, Dutta A. Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 2002; 161: 267273.
  • 43
    Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, et al. DNA replication licensing in somatic and germ cells. J Cell Sci 2004; 117: 58755886.
  • 44
    Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 2004; 204: 121130.
  • 45
    Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 25102517.
  • 46
    Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T, Ito H. Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep 2009; 21: 11891195.
  • 47
    Haruki T, Shomori K, Hamamoto Y, Taniguchi Y, Nakamura H, Ito H. Geminin expression in small lung adenocarcinomas: implication of prognostic significance. Lung Cancer 2011; 71: 356362.
  • 48
    Zhu W, Depamphilis ML. Selective killing of cancer cells by suppression of geminin activity. Cancer Res 2009; 69: 48704877.
  • 49
    Quaglia A, McStay M, Stoeber K, Loddo M, Caplin M, Fanshawe T, et al. Novel markers of cell kinetics to evaluate progression from cirrhosis to hepatocellular carcinoma. Liver Int 2006; 26: 424432.